|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study aimed to externally validate the ability of the prothrombin time-international normalized ratio to albumin ratio (PTAR), an objective and simple scoring system, to predict 90-day mortality in critically ill patients with cirrhosis.
|
30601338 |
2019 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on these observations, the Study Group proposed the following diagnostic criteria for ACLF in Japan: patients with cirrhosis and a Child-Pugh score of 5-9 should be diagnosed as having ACLF when a deterioration of liver function (serum bilirubin level ≥5.0 mg/dL and prothrombin time value ≤40% of the standardized values and/or international normalization rate ≥1.5) caused by severe liver damage develops within 28 days after acute insults, such as alcohol abuse, bacterial infection, gastrointestinal bleeding, or the exacerbation of underlying liver diseases.
|
29361652 |
2018 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, the easy Liver Fibrosis Test (eLIFT), a sum of points attributed to age, gender, gamma-glutamyl transpeptidase, aspartate transaminase, platelets, and prothrombin time, was developed for diagnosing advanced fibrosis and cirrhosis in chronic liver disease.
|
28710435 |
2017 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with cirrhosis included those with Child-Pugh Grade B (43%), preoperative moderate ascites (100%), a prothrombin time of ≥ 4 s (75%) and greater weight loss.
|
28520878 |
2017 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The prothrombin time once considered as an isolated measure of bleeding risk was rejected, and cirrhosis shifted from a purely hemorrhagic construct to a mixed and thrombosis-prone paradigm.
|
27801884 |
2017 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
After that, aspartate aminotransferase (AST), total bilirubin (TBIL), total bile acid (TBA), prothrombin time (PT), aspartate aminotransferase to platelet ratio index (APRI) and serum HBV DNA were confirmed as independent predictors of significant liver necroinflammation in CHB patients with cirrhosis by univariate analysis and multivariate analysis (p = 0.002, 0.044, 0.001, 0.014, 0.01 and 0.02 respectively).
|
27615602 |
2016 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of the FVL and prothrombin G20210A mutations were compared between patients with Budd-Chiari syndrome or PVT without cirrhosis and healthy individuals (controls) and between patients with cirrhosis, with and without PVT.
|
24793031 |
2014 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariable analysis identified alcohol consumption (odds ratio (OR) 6.4, 95% CI 1.3-30.1), aspartate aminotransferase >0.5 times the upper limit of normal (OR 15.4, 95% CI 1.9-122.6), and prothrombin time (OR 12.0, 95% CI 1.2-120.4), but not HBV DNA or quantitative HBsAg level, to be independent predictors of the presence of cirrhosis.
|
25449247 |
2014 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis identified baseline serum bilirubin >/=6 mg/dL (odds ratio [OR]: 5.61; 95% confidence interval [CI]: 1.66-21.61; P = 0.018), pre-existing cirrhosis (OR: 4.52; 95%CI: 1.26-30.42; P = 0.034), and baseline prothrombin time <40% (OR: 3.75; 95%CI: 1.03-43.86; P = 0.045) as independent determinants of the event.
|
15740488 |
2005 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prothrombin time is a benchmark for functional assessment in cirrhosis and Factor VII levels (FVII), crucial in determining the prothrombin time, are genetically determined.
|
15893284 |
2005 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The following thrombotic factors were evaluated in 68 hepatitis C patients with prothrombin activity >/= 80% (34 consecutive patients with extensive fibrosis and/or cirrhosis compared with 34 consecutive patients without extensive fibrosis and/or cirrhosis): factor V Leiden, G20210A prothrombin mutation, antithrombin, protein C and S deficiencies, hyperhomocysteinemia, elevated factor VIII level, and lupus anticoagulant.
|
15056097 |
2004 |
|
Cirrhosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preexisting cirrhosis and a prothrombin time (PT) of >30 s were associated with adverse outcome in 60.9% and 87.5% of patients, respectively.
|
12684909 |
2003 |
|
Cirrhosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The following were associated with a significantly higher rate of liver complications: age; birth in Asia, Europe, Mediterranean region, or Egypt; transmission by blood transfusion or sporadic cases; HCV genotypes 1b and 4 (compared with 1/1a); fibrosis stage 3 or 4 (cirrhosis); serum albumin; bilirubin; prothrombin time; and alpha-fetoprotein.
|
10655279 |
2000 |